Kategorije za Uncategorized

veterinary pharmacovigilance consulting

Veterinary pharmacovigilance consulting: alternatives to large pharma CROs for vet safety monitoring

August 27, 2026 8:27 am Published by

Veterinary pharmacovigilance can quickly become resource-intensive as companies work to maintain continuous oversight of veterinary product safety. Marketing authorisation holders must ensure appropriate pharmacovigilance expertise and keep their systems compliant, even when internal teams are already stretched or specialist veterinary PV resources are limited. For companies that need additional expertise or capacity, a large CRO... View Article

medical education service

Top-rated med ed agencies for pharma brands: a medical education service that delivers real value

August 26, 2026 7:35 am Published by

Pharmaceutical Medical Affairs teams are expected to deliver scientifically credible, relevant and compliant education while managing increasingly complex evidence, diverse healthcare professional needs and multiple communication channels. At the same time, limited internal capacity and demanding timelines can make it difficult to translate scientific objectives into consistent, high-quality educational programmes, making the right medical education... View Article

patient journey barriers

Patient journey barriers by therapeutic area and how to address them

August 20, 2026 11:48 am Published by

Understanding the patient journey from the first symptoms to diagnosis, treatment, and long-term disease management is essential for pharmaceutical companies developing truly patient-centric strategies. Yet patient journey barriers are rarely uniform. Diagnostic delays, referral gaps, limited treatment access, fragmented care, adherence challenges, and unmet information needs can occur at very different stages depending on the... View Article

veterinary pharmacovigilance service provider

Best vet PV service providers ranked: how to choose a veterinary pharmacovigilance service provider

August 19, 2026 8:41 am Published by

Veterinary pharmaceutical companies operate in an environment where maintaining product safety requires continuous oversight and specialised expertise. Effective veterinary pharmacovigilance requires marketing authorisation holders to maintain appropriate pharmacovigilance systems, continuously monitor product safety, manage safety information, maintain relevant documentation, and ensure that regulatory responsibilities are fulfilled throughout the lifecycle of veterinary medicinal products. As portfolios... View Article

regulatory affairs specialist

Regulatory affairs specialist: what do they do in pharma?

August 18, 2026 7:31 am Published by

Bringing a pharmaceutical product to market requires far more than generating strong scientific data. Companies must navigate complex regulatory requirements, coordinate documentation across multiple functions, meet strict submission timelines, respond to health authority questions, and maintain compliance after approval. Without the right regulatory oversight, even relatively small gaps can lead to incomplete submissions, additional authority... View Article

eCTD Publishing

eCTD publishing and life cycle management services for regulatory submissions

August 5, 2026 1:33 pm Published by

Preparing a regulatory submission involves much more than compiling documents into the correct structure. Successful eCTD publishing requires precise dossier assembly, technically compliant XML backbones, accurate life cycle operations, and a thorough understanding of regional regulatory requirements. As regulatory authorities continue to advance electronic submission standards and the industry prepares for broader adoption of eCTD... View Article

patient journey analysis

Patient journey analysis: what data sources are needed for end-to-end patient journey mapping

August 3, 2026 10:09 am Published by

Every pharmaceutical company collects enormous amounts of data. Electronic health records, claims databases, patient support programs, Medical Affairs activities, market research, and real-world evidence all generate valuable insights every day. Yet despite this wealth of information, many organizations still struggle to answer fundamental questions: Why are patients diagnosed too late? Where do they discontinue treatment?... View Article

patient journey insights

Patient journey insights: how to integrate patient journey insights into payer strategy

July 31, 2026 8:51 am Published by

Developing a successful payer strategy has become far more complex than demonstrating clinical efficacy alone. Today’s reimbursement decisions increasingly depend on whether pharmaceutical companies can clearly demonstrate real-world value, address unmet needs, and show how their therapy improves outcomes across the entire care pathway. An effective payer strategy should be built around real-world patient experiences... View Article

environmental risk assessment services

Environmental risk assessment services for pharma submissions: how to choose the right partner

July 30, 2026 9:54 am Published by

Bringing a medicinal product to market requires far more than demonstrating quality, safety, and efficacy. Companies must also demonstrate that the product is unlikely to pose an unacceptable risk to the environment. An incomplete or poorly prepared Environmental Risk Assessment (ERA) can lead to regulatory questions, additional data requests, prolonged review timelines, and unnecessary costs.... View Article

veterinary GMP

EU Veterinary GMP: What manufacturers need to do under the New Regulatory framework

July 29, 2026 2:53 pm Published by

The introduction of the new EU Veterinary GMP framework represents a significant regulatory change for manufacturers of veterinary medicinal products. Since 16 July 2026, dedicated Good Manufacturing Practice (GMP) requirements for veterinary medicinal products and veterinary active substances have applied under Commission Implementing Regulations (EU) 2025/2091 and (EU) 2025/2154, adopted pursuant to Regulation (EU) 2019/6.... View Article